- Home
- WU vs DNLI Comparison
WU vs DNLI Comparison
Compare WU & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WU | DNLI |
|---|---|---|
| Founded | 1851 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | 2006 | 2017 |
Fundamental Metrics
Financial Performance| Metric | WU | DNLI |
|---|---|---|
| Price | $8.76 | $18.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $8.75 | ★ $32.64 |
| AVG Volume (30 Days) | ★ 8.2M | 1.4M |
| Earning Date | 10-23-2025 | 11-06-2025 |
| Dividend Yield | ★ 10.80% | N/A |
| EPS Growth | ★ 18.91 | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $4,100,500,000.00 | N/A |
| Revenue This Year | $0.08 | N/A |
| Revenue Next Year | $0.59 | $94,232.03 |
| P/E Ratio | $3.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.85 | $10.57 |
| 52 Week High | $11.95 | $26.18 |
Technical Indicators
Market Signals| Indicator | WU | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 51.67 | 56.96 |
| Support Level | $8.14 | $18.74 |
| Resistance Level | $8.84 | $19.63 |
| Average True Range (ATR) | 0.25 | 0.98 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 57.62 | 47.47 |
Price Performance
Historical ComparisonAbout WU Western Union Company (The)
Western Union provides domestic and international money transfers through its global network of over 500,000 outside agents. The company handled almost 290 million transactions in 2024 and is the largest money transfer company in the world.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.